Lanean...
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease
BACKGROUND: Bapineuzumab, a humanized anti–amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer’s disease. METHODS: We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer’s disease — one...
Gorde:
| Egile Nagusiak: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2014
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4159618/ https://ncbi.nlm.nih.gov/pubmed/24450891 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1304839 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|